Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
August 10 2017 - 7:00AM
Akari Therapeutics (NASDAQ:AKTX), an emerging growth,
clinical-stage biopharmaceutical company, announced today that
Clive Richardson, Chief Operations Officer, and Dr. Wynne
Weston-Davies, Medical Director, will present at the 37th Annual
Canaccord Genuity Growth Conference on August 10th, 2017, in
Boston, Massachusetts. The company is scheduled to present at
2:00 p.m. EDT.
About Akari Therapeutics Plc
Akari is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics to
treat orphan autoimmune and inflammatory diseases and, in
particular, those where the complement system or leukotrienes or
both complement and leukotrienes together play a primary role in
disease progression. Akari’s lead drug, Coversin is a C5 complement
inhibitor, currently being evaluated in Paroxysmal Nocturnal
Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).
In addition to its C5 inhibitory activity, Coversin independently
and specifically inhibits leukotriene B4 (LTB4) activity.
Akari intends to evaluate Coversin in two conditions, the skin and
eye diseases Bullous Pemphigoid and Atopic Keratoconjunctivitis,
where the dual action of Coversin on both C5 and LTB4 may be
beneficial. Akari is also developing other tick derived proteins,
including long acting versions.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control. Such risks and uncertainties for our company
include, but are not limited to: an inability or delay in obtaining
required regulatory approvals for Coversin and any other product
candidates, which may result in unexpected cost expenditures; risks
inherent in drug development in general; uncertainties in obtaining
successful clinical results for Coversin and any other product
candidates and unexpected costs that may result therefrom; failure
to realize any value of Coversin and any other product candidates
developed and being developed in light of inherent risks and
difficulties involved in successfully bringing product candidates
to market; inability to develop new product candidates and support
existing product candidates; the approval by the FDA and EMA and
any other similar foreign regulatory authorities of other competing
or superior products brought to market; risks resulting from
unforeseen side effects; risk that the market for Coversin may not
be as large as expected; inability to obtain, maintain and enforce
patents and other intellectual property rights or the unexpected
costs associated with such enforcement or litigation; inability to
obtain and maintain commercial manufacturing arrangements with
third party manufacturers or establish commercial scale
manufacturing capabilities; the inability to timely source adequate
supply of our active pharmaceutical ingredients from third party
manufacturers on whom the company depends; our inability to obtain
additional capital on acceptable terms, or at all; unexpected cost
increases and pricing pressures; uncertainties of cash flows and
inability to meet working capital needs; and risks and other risk
factors detailed in our public filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K filed
on March 23, 2016. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release and we
undertake no obligation to update or revise any of these statements
to reflect events or circumstances occurring after this press
release. We caution investors not to place considerable reliance on
the forward-looking statements contained in this press release.
Contact:
Investor Contact:
The Trout Group
Lee Stern
lstern@troutgroup.com
646–378–2922
Media Contact:
Susan Forman / Laura Radocaj
Dian Griesel Int'l.
(212) 825-3210
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024